11 research outputs found
Recommended from our members
Spatial distribution of COVID-19 infections and vaccinations in Austin, Texas
In this report, we estimate the spatial distribution of SARS-CoV-2 infections and vaccine administration across Austin, TX. We find marked geographic differences in these outcomes. In particular, ZIP codes on the western side of the city tend to have higher vaccine coverage and lower estimated cumulative infections than ZIP codes on the eastern side of the city. These differences mirror disparities in social vulnerability, as measured by the CDC's social vulnerability index (SVI), which tends to be higher in eastern ZIP codes than in western ZIP codes.Integrative Biolog
Recommended from our members
COVID-19 scenario projections for Austin, Texas - August 2021
To support public health decision-making and healthcare planning, we developed a model for the five-county Austin-Round Rock Metropolitan Statistical Area (henceforth Austin) that can provide real-time estimates of the prevalence and transmission rate of COVID-19 and project healthcare needs into the future. The model incorporates key epidemiological characteristics of the disease, demographic information for Austin, local vaccination estimates, and local mobility data from anonymized cell phone traces. It uses daily COVID-19 hospitalization data to estimate the changing transmission rate and prevalence of the disease. In this report, we use COVID-19 hospitalization data for Austin from March 13, 2020 to July 28, 2021 to estimate the state of the pandemic in the summer of 2021 and project hospitalizations through November of 2021.Integrative Biolog
Recommended from our members
Heterogeneous burden of the COVID-19 pandemic in central Texas
The heterogeneous burden of the COVID-19 pandemic within and across US cities has been linked to myriad risk factors including occupation, socioeconomic status, and race [1-3]. Here we use fine-grain, anonymized hospitalization data to estimate the heterogeneous impact of the COVID-19 pandemic on Austin, Texas across age groups and ZIP codes. We provide estimates for (1) the percent of the population infected as of January 11, 2021 and (2) the reporting rate of infections, and relate these estimates to the CDC Social Vulnerability Index (SVI) for each ZIPIntegrative Biolog
Global urban environmental change drives adaptation in white clover
Urbanization transforms environments in ways that alter biological evolution. We examined whether urban environmental change drives parallel evolution by sampling 110,019 white clover plants from 6169 populations in 160 cities globally. Plants were assayed for a Mendelian antiherbivore defense that also affects tolerance to abiotic stressors. Urban-rural gradients were associated with the evolution of clines in defense in 47% of cities throughout the world. Variation in the strength of clines was explained by environmental changes in drought stress and vegetation cover that varied among cities. Sequencing 2074 genomes from 26 cities revealed that the evolution of urban-rural clines was best explained by adaptive evolution, but the degree of parallel adaptation varied among cities. Our results demonstrate that urbanization leads to adaptation at a global scale
Recommended from our members
COVID-19 scenario projections for Austin, Texas - July 19, 2021
To support public health decision-making and healthcare planning, we developed a model for the five-county Austin-Round Rock Metropolitan Statistical Area (henceforth Austin) that can provide real-time estimates of the prevalence and transmission rate of COVID-19 and project healthcare needs into the future. The model incorporates key epidemiological characteristics of the disease, demographic information for Austin, local vaccination estimates, and local mobility data from anonymized cell phone traces. It uses daily COVID-19 hospitalization data to estimate the changing transmission rate and prevalence of disease. The framework can be readily applied to provide pandemic situational awareness and short-term healthcare projections in other cities around the US. In this report, we use COVID-19 hospitalization data for Austin from March 13, 2020 to July 13, 2021 to estimate the state of the pandemic in mid-summer of 2021 and project hospitalizations up to October, 2021.Integrative Biolog
Disproportionate impacts of COVID-19 in a large US city.
COVID-19 has disproportionately impacted individuals depending on where they live and work, and based on their race, ethnicity, and socioeconomic status. Studies have documented catastrophic disparities at critical points throughout the pandemic, but have not yet systematically tracked their severity through time. Using anonymized hospitalization data from March 11, 2020 to June 1, 2021 and fine-grain infection hospitalization rates, we estimate the time-varying burden of COVID-19 by age group and ZIP code in Austin, Texas. During this 15-month period, we estimate an overall 23.7% (95% CrI: 22.5-24.8%) infection rate and 29.4% (95% CrI: 28.0-31.0%) case reporting rate. Individuals over 65 were less likely to be infected than younger age groups (11.2% [95% CrI: 10.3-12.0%] vs 25.1% [95% CrI: 23.7-26.4%]), but more likely to be hospitalized (1,965 per 100,000 vs 376 per 100,000) and have their infections reported (53% [95% CrI: 49-57%] vs 28% [95% CrI: 27-30%]). We used a mixed effect poisson regression model to estimate disparities in infection and reporting rates as a function of social vulnerability. We compared ZIP codes ranking in the 75th percentile of vulnerability to those in the 25th percentile, and found that the more vulnerable communities had 2.5 (95% CrI: 2.0-3.0) times the infection rate and only 70% (95% CrI: 60%-82%) the reporting rate compared to the less vulnerable communities. Inequality persisted but declined significantly over the 15-month study period. Our results suggest that further public health efforts are needed to mitigate local COVID-19 disparities and that the CDC's social vulnerability index may serve as a reliable predictor of risk on a local scale when surveillance data are limited
Global urban environmental change drives adaptation in white clover
Urbanization transforms environments in ways that alter biological evolution. We examined whether urban environmental change drives parallel evolution by sampling 110,019 white clover plants from 6169 populations in 160 cities globally. Plants were assayed for a Mendelian antiherbivore defense that also affects tolerance to abiotic stressors. Urban-rural gradients were associated with the evolution of clines in defense in 47% of cities throughout the world. Variation in the strength of clines was explained by environmental changes in drought stress and vegetation cover that varied among cities. Sequencing 2074 genomes from 26 cities revealed that the evolution of urban-rural clines was best explained by adaptive evolution, but the degree of parallel adaptation varied among cities. Our results demonstrate that urbanization leads to adaptation at a global scale
Global urban environmental change drives adaptation in white clover
Urbanization transforms environments in ways that alter biological evolution. We examined whether urban environmental change drives parallel evolution by sampling 110,019 white clover plants from 6169 populations in 160 cities globally. Plants were assayed for a Mendelian antiherbivore defense that also affects tolerance to abiotic stressors. Urban-rural gradients were associated with the evolution of clines in defense in 47% of cities throughout the world. Variation in the strength of clines was explained by environmental changes in drought stress and vegetation cover that varied among cities. Sequencing 2074 genomes from 26 cities revealed that the evolution of urban-rural clines was best explained by adaptive evolution, but the degree of parallel adaptation varied among cities. Our results demonstrate that urbanization leads to adaptation at a global scale
Risk of COVID-19 after natural infection or vaccinationResearch in context
Summary: Background: While vaccines have established utility against COVID-19, phase 3 efficacy studies have generally not comprehensively evaluated protection provided by previous infection or hybrid immunity (previous infection plus vaccination). Individual patient data from US government-supported harmonized vaccine trials provide an unprecedented sample population to address this issue. We characterized the protective efficacy of previous SARS-CoV-2 infection and hybrid immunity against COVID-19 early in the pandemic over three-to six-month follow-up and compared with vaccine-associated protection. Methods: In this post-hoc cross-protocol analysis of the Moderna, AstraZeneca, Janssen, and Novavax COVID-19 vaccine clinical trials, we allocated participants into four groups based on previous-infection status at enrolment and treatment: no previous infection/placebo; previous infection/placebo; no previous infection/vaccine; and previous infection/vaccine. The main outcome was RT-PCR-confirmed COVID-19 >7–15 days (per original protocols) after final study injection. We calculated crude and adjusted efficacy measures. Findings: Previous infection/placebo participants had a 92% decreased risk of future COVID-19 compared to no previous infection/placebo participants (overall hazard ratio [HR] ratio: 0.08; 95% CI: 0.05–0.13). Among single-dose Janssen participants, hybrid immunity conferred greater protection than vaccine alone (HR: 0.03; 95% CI: 0.01–0.10). Too few infections were observed to draw statistical inferences comparing hybrid immunity to vaccine alone for other trials. Vaccination, previous infection, and hybrid immunity all provided near-complete protection against severe disease. Interpretation: Previous infection, any hybrid immunity, and two-dose vaccination all provided substantial protection against symptomatic and severe COVID-19 through the early Delta period. Thus, as a surrogate for natural infection, vaccination remains the safest approach to protection. Funding: National Institutes of Health